Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.
Dela sida
Sponsrat innehåll

Targeting NASH: THR-β, FXR, GLP-1R, and More

In March 2024, the U.S. FDA approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis).

Nonalcoholic steatohepatitis (NASH) presents a significant public health challenge. Several biomarkers and drug targets are known to be involved in NASH, and their dysregulation contributes to NASH pathogenesis. Sino Biological offers recombinant drug targets related to NASH to support the development of innovative therapies for NASH therapies and to address comorbidities such as diabetes. 

Featured Products for NASH Drug Targets

Sino Biological has developed a panel of high-quality recombinant proteins for NASH drug targets, including FASN, THR-β, NR1H4/FXR, GLP-1R, PPARA, FGF19, FGF21, and ACLY. These proteins are HPLC-verified for high purity and are trusted by users as indicated by citations in top-tier journals. The antibodies for NASH drug targets are also available with a variety of applications, such as IHC-P, ICC/IF,WB, ELISA, and IP.

Learn more about drug targets for NASH.

Download poster to gain more valuable insights for NASH targets.

Find out more drug targets in different research fields.

Sino Biological Europe GmbH
Düsseldorfer Str. 40
65760 Eschborn
VAT nummer: DE323950120


Sino Biological Europe GmbH

Sänd till en kollega